Find a Cancer Provider

Are you a referring physician?
within
I am searching for a
Reset Form
Amy S. Clark, MD, MSCE

Amy S. Clark, MD, MSCE Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Clark is employed by Penn Medicine.

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Internal Medicine, 2009
  • Medical Oncology, 2012

Clinical Expertise:

  • Adjuvant Chemotherapy
  • Aromatase Inhibitor
  • Atypical Ductal Hyperplasia
  • Brca
  • Breast Cancer
  • Breast Cancer Chemotherapy
  • Breast Cancer During Pregnancy
  • Breast Cancer Follow Up
  • Breast Cancer Genetics
  • Breast Cancer High-Risk Counseling
  • Carcinoma In Situ of Breast
  • Cystosarcoma Phyllodes
  • ER Negative Breast Cancer
  • ER Positive Breast Cancer
  • Family History of Breast Cancer
  • Herceptin
  • Hereditary Breast and Ovarian Cancer
  • Immunotherapy
  • Inflammatory Breast Cancer (IBC)
  • Invasive Breast Cancer
  • Lobular Neoplasia
  • Male Breast Cancer
  • Neoadjuvant Chemotherapy
  • Sentinel Lymph Node Biopsy
  • Tamoxifen
  • Triple-Negative Breast Cancer
Show All Expertise

Practice Locations and Appointments

  • Rena Rowan Breast Center

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 3rd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-7366 (PENN)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Penn State Milton S. Hershey Medical Center
Residency: Boston Medical Center (Formerly Boston City Hospital)
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Society of Clinical Oncology, National

Hospital Affiliation

Dr. Clark is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.

Selected Publications:

Esserman L, Yeee D, DeMichele A, Yau C, Issacs C, Symmans WF, Albain K, Chen Yunn-yi, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocoo A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Yang S, Adams A, Chein AJ, Forero-Torres T, Stringer-Reasor E, Wallace AM, Pusztai L, Boughry JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Visvcusi RK, Lo S: Disease-free survival correlates with pathologic complete response in the adaptively randomized I-SPY2 trial of stage 2/3 breast cancer The Lancet : 2020.

McDonald E, Doot RK, Carlin SD, Pantel A, Shah PD, Clark AS, Desai H, Kelly G, Young AJ, Pryma DA, Farewell MD, Nayak A, Lee H, Schubert EK, Makvandi M, Xiober A, Tchou J, DeMichele A, Feldman M, Domchek SM, Mach RH, Maxwell KN, Manoff: PARP Imaging in Breast Bancer JAMA Oncology : 2020.

Yau C, DeMichele A, Symmans W, Pusztai L, Yee D, CLark AS, Hatzis C, Matthews JB, Carter J, Chen Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, Sahoo S, Albian KS, Chien A, Edminston KK, Elias AD, Ellis ED, Euhus DM, Han HS, Issacs C, Kahn OJ, Lang JE, Lu J, Meisel JL, Mitri Z, Nanda R, Northfelt DW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yung R, Hylton NM, Boughey JC, Melisko ME, Perlmutter J, Rugo HS, Schwab R, Van't Veer LJ, Berry DA, Esserman LJ: Site of recurrence after neoadjuvant therapy: clues to biology and impact on endpoints San Antonio Texas Breast Cancer Symposium® : 2019.

Nivar I, Kaufmann T, Bayne L, Goodspeed B, Chodosh L, Feldman M, Wileyto P, Clark A, DeMichele A: Patient attitudes, experience and results of screening for minimal residual disease (MRD) for therapeutic intervention San Antonio Texas Breast Cancer Symposium® : 2019.

Bardia, A., Hurvitz, S., DeMichele, A., Clark, A.S., Zelnak, A., Yardley, D., Karuturi, M., Sanft, T., Blau, S., Hart, L., Mia, C., Caria, N., Purkayastha, D., Mistry, A., Moulder, S.: Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): efficacy, safety, and biomarker results ASCO 2019 – TRINITI-1, Chicago Illinois : 2019.

Dreyfuss AD, Barsky AR, Taunk NK, Clark AS, Freedman GM: The Efficacy and Safety of Hypofractionated Radiotherapy with Concurrent Anti-HER-2 Therapy Following Breast-Conserving Therapy for Breast Cancer The Breast Journal : 2019.

Mankoff DA, Clark AS: PET oestrogen receptor imaging: ready for the clinic? The Lancet Oncology : 2019.

Elmi, A., Makvandi, M., Weng, C.C., Hou, C., Clark, AS., Mach, R.H., Mankoff, D.A.: Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT. Clin Cancer Res : 2019.

Pomponio MK, Keele LJ, Fox KR, Clark AS, Matro JM, Shulman LN, Tchou JC: Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple negative breast cancer? Breast Cancer Research and Treatment : 2019.

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A, Chien JA, Forero-Torres A, Ellis E, Han H, Clark AS, Albain K, Boughey J, Jaskowiak N, Elias A, Isaacas C, Kemmer K, Helsten T, Maure M, Stinger-Reasor E, Parker C, Lee M, Haddad T, Cohen R, Asare S, Wilson A, Hirst G, Singhrao R, Asare A, Matthews J, Berry S, Schwab R, Symmans W, van't Veer L, Yee D, DeMichele A, Hylton N, Oerlmutter J, Rugo H, Berry D, Esserman L: Pembrolizumab for Early-Stage, High-Risk, HER2-Negative Breast Cancer: Results from the I-SPY2 Trial JCO : 2019.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 662-7096
Patient appointments: 800-789-7366 (PENN)